Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | MTOR | P42345 | 1/20 | 0.69 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.69 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.69 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.56 |
| ▸ | ST6GAL1 | P15907 | 6/20 | 0.54 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6060610 | 1.00 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| Hydrochloric Acid SCHEMBL11852751 | 0.99 | LMNA (0.67) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL12724455 | 0.91 | LMNA (0.60) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL5824295 | 0.90 | LMNA (0.56) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL6932191 | 0.90 | LMNA (0.56) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL331768 | 0.90 | LMNA (0.70) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL30608768 | 0.90 | LMNA (0.74) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL25382718 | 0.89 | LMNA (0.64) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL2031869 | 0.89 | LMNA (0.55) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL28322026 | 0.89 | LMNA (0.64) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038850-A1 | LIPID NANOPARTICLES AND METHODS FOR SENSITIZING RESPONSE TO AN IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-20 | — | — | WO | claimed |
| EP-4384635-A1 | IN SITU EPITRANSCRIPTOMIC PROFILING | The Broad Institute Inc. (US) | 2024-06-19 | — | — | EP | claimed |
| WO-2024123812-A1 | FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES | SHATTUCK LABS, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| CN-117886868-A | Preparation method of 5' -DMT nucleoside compound | 天津奥瑞芙生物医药有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-116964220-A | Multiplex analysis of RNA and DNA modifications | 阿丽达生物科学公司 | 2023-10-27 | — | — | CN | claimed |
| EP-4251760-A1 | MULTIPLEXED PROFILING OF RNA AND DNA MODIFICATIONS | Alida Biosciences, Inc. (US) | 2023-10-04 | — | — | EP | claimed |
| US-11773425-B2 | Multiplexed profiling of RNA and DNA modifications | Alida Biosciences Inc. (US) | 2023-10-03 | — | — | US | claimed |
| WO-2022115608-A9 | MULTIPLEXED PROFILING OF RNA AND DNA MODIFICATIONS | ALIDA BIOSCIENCES, INC. (US) | 2023-06-15 | — | — | WO | claimed |
| WO-2023018756-A1 | IN SITU EPITRANSCRIPTOMIC PROFILING | THE BROAD INSTITUTE, INC. (US) | 2023-02-16 | — | — | WO | claimed |
| WO-2022140380-A1 | METABOLOMIC SIGNATURES FOR PREDICTING, DIAGNOSING, AND PROGNOSING CHRONIC PANCREATITIS | PANCREOMICS LLC (US) | 2022-06-30 | — | — | WO | claimed |
| US-20120116067-A1 | METHOD FOR THE SOLID PHASE-BASED PRODUCTION OF PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | UNIVERSITAET HAMBURG (DE) | 2012-05-10 | — | — | US | claimed |
| EP-2427470-A1 | METHOD FOR THE SOLID PHASE-BASED PRODUCTION OF PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | Universität Hamburg (DE) | 2012-03-14 | — | — | EP | claimed |
| WO-2011113607-A1 | MOLECULARLY IMPRINTED POLYMERS FOR ELIMINATING METABOLITES | FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH (DE) | 2011-09-22 | — | — | WO | claimed |
| US-20110137023-A1 | METHOD FOR PRODUCING PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | UNIVERSITAET HAMBURG (DE) | 2011-06-09 | — | — | US | claimed |
| EP-2321330-A1 | METHOD FOR PRODUCING PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | Universität Hamburg (DE) | 2011-05-18 | — | — | EP | claimed |
| US-20110028705-A1 | METHOD FOR THE STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS COMPOUNDS | UNIVERSITAET HAMBURG (DE) | 2011-02-03 | — | — | US | claimed |
| EP-2262820-A1 | METHOD FOR THE STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS COMPOUNDS | Universität Hamburg (DE) | 2010-12-22 | — | — | EP | claimed |
| WO-2010127666-A1 | METHOD FOR THE SOLID PHASE-BASED PRODUCTION OF PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | UNIVERSITÄT HAMBURG (DE) | 2010-11-11 | — | — | WO | claimed |
| WO-2010015245-A1 | METHOD FOR PRODUCING PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | UNIVERSITÄT HAMBURG (DE) | 2010-02-11 | — | — | WO | claimed |
| WO-2009121347-A1 | METHOD FOR THE STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS COMPOUNDS | UNIVERSITÄT HAMBURG (DE) | 2009-10-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110137023-A1 | METHOD FOR PRODUCING PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | TYMP, PNP, NUDT1 | LMNA 3246/4885THRB 4815/4885MTOR 1502/4885 |
| US-20110028705-A1 | METHOD FOR THE STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS COMPOUNDS | MTAP, PHOSPHO1, PNKP | LMNA 3041/4885THRB 1384/4885MTOR 1144/4885 |
| US-20120116067-A1 | METHOD FOR THE SOLID PHASE-BASED PRODUCTION OF PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | PNP, TYMP, DPYD | LMNA 2594/4885THRB 4656/4885MTOR 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.